Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185208 · ClinicalTrials.gov registry record · Phase 4
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
A Phase 4 study of Mild Cognitive Impairment, sponsored by Ariel Gildengers, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT03185208: Completed Phase 4 study of Mild Cognitive Impairment, sponsored by Ariel Gildengers, MD.
NCT03185208 is a Phase 4 study of Mild Cognitive Impairment that has completed, run by Ariel Gildengers, MD. The registered enrollment target is 83 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185208, a Phase 4 study of Mild Cognitive Impairment, has completed, sponsored by Ariel Gildengers, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.
Primary Outcome
California Verbal Learning Test II. Long-delay free recall. Scores range from 0 - 16; higher means better.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Lithium Carbonate
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 4 |
What the finished NCT03185208 record still lists
NCT03185208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03185208 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03185208 about?
NCT03185208 is a clinical study titled "Lithium As a Treatment to Prevent Impairment of Cognition in Elders". Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more rese...
What is the current status of trial NCT03185208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2018-02-02. Estimated completion is 2024-08-06.
What conditions does trial NCT03185208 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT03185208?
The interventions under investigation include: Placebo oral capsule (DRUG), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT03185208?
This trial is sponsored by Ariel Gildengers, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03185208 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03185208's enrollment target sits among peer trials
83 101st of 205 higher than 105 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Water-based Activity to Enhance Recall in Veterans
ACTIVE NOT RECRUITING · Phase 4
-
Combination Treatment Study for Memory Impairment and Depression
COMPLETED · Phase 4
-
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
COMPLETED · Phase 4
-
Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
COMPLETED · Phase 4
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI